A NEXN gene high expression type osteosarcoma cell line and its construction method and application
By constructing the NEXN gene highly expressed osteosarcoma cell line and establishing a lung metastasis model, the problem of treating osteosarcoma lung metastasis in the prior art is solved, providing an effective tool for drug screening and research, and improving treatment efficiency.
Patent Information
- Application Number
- CN202411225690.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-09-03
AI Technical Summary
The prior art has limited efficacy in treating lung metastasis in osteosarcoma, and lacks effective animal models, which leads to treatment difficulties, especially second-line chemotherapy and immunotherapy, targeted treatment is prone to drug resistance, surgical resection and metastasis ablation It is only suitable for small isolated metastases and cannot cure lung metastases.
Construct the NEXN gene high-expression osteosarcoma cell line, and by inserting the NEXN gene into the lentiviral vector plasmid, packaging the recombinant lentivirus, infecting the osteosarcoma cells, constructing the highly expressed cell line, and inoculating it into the animal's tibial marrow cavity to establish Osteosarcoma model of pulmonary metastasis, used for drug screening and research.
Provide a model of pulmonary metastatic osteosarcoma that can be used for drug screening and research, which can simulate the pathological and pharmacological characteristics of osteosarcoma, promote and apply it, help solve the problem of treating pulmonary metastatic osteosarcoma in the prior art, and improve research and The efficiency of treatment.
Smart Images

Figure CN118726488B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and in particular relates to a NEXN gene high-expression osteosarcoma cell line and a construction method and application thereof. Background Art
[0002] Osteosarcoma (OS) is a highly malignant tumor with an annual incidence of about 2-3 per million. It is divided into three types: intramedullary, surface, and extraosseous. The diagnosis is mainly confirmed by a combination of clinical, imaging, and pathology. Since Rosen et al. introduced neoadjuvant chemotherapy to treat osteosarcoma in the 1970s, the 5-year survival rate of osteosarcoma patients has greatly improved, from less than 20% to 66-82%. Therefore, neoadjuvant chemotherapy combined with surgery has also become the standard treatment for osteosarcoma patients in the past 50 years.
[0003] Osteosarcoma patients are prone to hematogenous metastasis to the lungs. Once lung metastasis occurs, the treatment effect is very poor. The main treatments for lung metastasis are second-line chemotherapy, third-line chemotherapy, stereotactic radiotherapy, palliative surgical resection, and metastatic ablation. Although in the past 10 years, with the introduction of targeted drugs such as regorafenib, sorafenib, sorafenib combined with everolimus, apatinib and other tyrosine kinase inhibitors (TKIs), the initial treatment can effectively reduce lung metastases, but its efficacy is limited, and it is very easy to develop drug resistance. Immunotherapy such as PD-1 and PD-L1 is not very effective for patients with advanced OS. The effects of second-line chemotherapy and immunotherapy are not ideal, targeted therapy is prone to drug resistance, surgical resection is prone to recurrence, and metastatic ablation is only suitable for small isolated metastases. These can only slow down the progression of lung metastasis, and there is a problem that lung metastasis cannot be cured. Currently, the 5-year survival rate of patients with OS and pulmonary metastasis is below 20%, the treatment effect is unsatisfactory, and the prognosis is extremely poor, which is an insurmountable "bottleneck" problem in clinical treatment.
[0004] Currently, there is a lack of effective animal models of osteosarcoma with lung metastasis for studying therapeutic drugs for osteosarcoma with lung metastasis. Therefore, how to overcome the shortcomings of the existing technology is an urgent problem to be solved in this technical field. Summary of the invention
[0005] The purpose of the present invention is to solve the deficiencies of the prior art and to provide a NEXN gene highly expressed osteosarcoma cell line and a construction method and application thereof.
[0006] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0007] The first aspect of the present invention provides a method for constructing a NEXN gene high expression type osteosarcoma cell line, comprising the following steps:
[0008] Step (1), plasmid construction:
[0009] The coding sequence of the NEXN gene was inserted into the downstream of the CMV promoter of the lentiviral vector plasmid pLV4ltr-PGK-ZsGreen(2A)Puro-CMV to obtain the NEXN overexpression lentiviral vector plasmid pLV4ltr-PGK-ZsGreen(2A)Puro-CMV-NEXN;
[0010] The coding sequence of the NEXN gene is shown in SEQ ID NO.11;
[0011] Step (2), lentiviral packaging: the NEXN overexpression lentiviral vector plasmid pLV4ltr-PGK-ZsGreen(2A)Puro-CMV-NEXN obtained in step (1) is co-transfected into 293T cells together with PSPAX2 and PMD2.G plasmids using a liposome method to obtain a recombinant lentivirus;
[0012] Step (3), cell line construction: using the recombinant lentivirus prepared in step (2) to infect human osteosarcoma cell line cells, replacing the culture medium with a screening medium 24 hours after infection, and adding puromycin to the screening culture medium for screening to obtain positive cells; the human osteosarcoma cell line cells are human osteosarcoma cell line HOS cells or human osteosarcoma cell line 143B cells; wherein the screening culture medium replaced 24 hours after infection is 89% MEM + 10% FBS + 1% dual antibody;
[0013] Step (4), expansion culture: the screened positive cells are expanded and cultured to construct an osteosarcoma cell line with high expression of the NEXN gene.
[0014] Furthermore, in step (2), during transfection, the transfection culture medium used was 90% DMEM + 10% FBS.
[0015] Furthermore, in step (3), puromycin is added to the screening culture medium to a concentration of 1 μg / mL.
[0016] The second aspect of the present invention provides a method for constructing a NEXN gene high-expression osteosarcoma cell line and a NEXN gene high-expression osteosarcoma cell line obtained by the construction.
[0017] The third aspect of the present invention provides a method for constructing a NEXN gene high-expressing osteosarcoma cell line and application of the constructed NEXN gene high-expressing osteosarcoma cell line in drug screening.
[0018] The fourth aspect of the present invention provides a method for constructing an animal model of osteosarcoma with lung metastasis, wherein the NEXN gene highly expressed osteosarcoma cell line is constructed by the above-mentioned method for constructing a NEXN gene highly expressed osteosarcoma cell line, and the method comprises the following steps:
[0019] The osteosarcoma cell line with high expression of NEXN gene was inoculated into the tibia bone marrow cavity of animals to obtain the osteosarcoma model animal with lung metastasis.
[0020] Furthermore, the animal is a mouse.
[0021] Furthermore, the NEXN gene high-expression osteosarcoma cell line was injected into the bilateral tibial medullary cavity of the animals, with an injection dose of 200-300 cells per side.
[0022] A fifth aspect of the present invention provides a method for constructing an osteosarcoma model animal with lung metastasis, and use of the constructed osteosarcoma model animal with lung metastasis in screening therapeutic drugs for osteosarcoma with lung metastasis.
[0023] In the present invention, the expression level of NEXN gene in the NEXN gene high-expression osteosarcoma cell line is 3-6 times the expression level of NEXN gene in the parental osteosarcoma cell line.
[0024] Compared with the prior art, the present invention has the following beneficial effects:
[0025] The NEXN gene high-expression osteosarcoma cell line constructed by the present invention can be used to construct an osteosarcoma model animal with lung metastasis, can also be used for drug screening, and can be used for pathological and pharmacological research on osteosarcoma lung metastasis, and is easy to promote and apply. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 is the protein interaction network of the target gene set members; A is the PPI network of genes that interact with NEXN; B is the core network that includes NEXN in the PPI network of the target gene set;
[0027] Figure 2: Statistical graphs of mRNA differential expression; A is a statistical graph of RGS5 mRNA differential expression between peritumoral tissue (NC) and tumor tissue (OS); B is a statistical graph of NEXN mRNA differential expression between peritumoral tissue (NC) and tumor tissue (OS); C is a statistical graph of EDN1 mRNA differential expression between peritumoral tissue (NC) and tumor tissue (OS); D is a statistical graph of CAV1 mRNA differential expression between peritumoral tissue (NC) and tumor tissue (OS); E is a statistical graph of RGS5 mRNA differential expression between patients without metastasis (NM-OS) and patients with metastasis (M-OS); F is a statistical graph of NEXN mRNA differential expression between patients without metastasis (NM-OS) and patients with metastasis (M-OS); G is a statistical graph of EDN1 mRNA differential expression between patients without metastasis (NM-OS) and patients with metastasis (M-OS); H is a statistical graph of CAV1 mRNA differential expression between patients without metastasis (NM-OS) and patients with metastasis (M-OS);
[0028] Figure 3 This is a fluorescence photo of RNA FISH;
[0029] Figure 4 The WB photos and grayscale statistical graphs of the differential expression of NEXN gene in osteosarcoma and control tissues; A is the WB photo of the patient group without lung metastasis; B is the grayscale value statistical analysis graph of NEXN protein expression in the patient group without lung metastasis; C is the WB photo of the patient group with lung metastasis; D is the grayscale value statistical analysis graph of NEXN protein expression in the patient group with lung metastasis; * represents P < 0.05, *** represents P < 0.0001;
[0030] Figure 5 It is used as a control for qPCR detection of NEXN mRNA expression in hFOB1.19 and osteosarcoma cells;
[0031] Figure 6 is the structure diagram of the recombinant plasmid;
[0032] Figure 7 The results of the NEXN expression test in HOS and 143B cells; A is the expression of NEXN in HOS cells after transfection detected by qPCR; B is the expression of NEXN in 143B cells after transfection detected by qPCR; C is the expression of NEXN protein in HOS and 143B cells after transfection detected by Western Blot; D is the quantitative analysis result of NEXN protein expression; *** represents P < 0.01;
[0033] Figure 8The figure shows the effect of NEXN on the viability of osteosarcoma cells; A is the CCK-8 experiment of HOS cells; B is the CCK-8 experiment of 143B cells; ****** represents the comparison between the overexpression group and the negative control group and the blank control group, P < 0.01;
[0034] Fig. 9 Figure 1 is the effect of NEXN on the lateral migration ability of HOS and 143B cells; A is the scratch image of HOS cells; B is the comparison result of the relative scratch healing rate of HOS cells; C is the scratch image of 143B cells; D is the comparison result of the relative scratch healing rate of 143B cells, *** represents the comparison between the overexpression group and the negative control group and the blank control group, P < 0.01;
[0035] Fig.10 Figure 2 is the effect of NEXN on the invasion ability of HOS and 143B cells; A is a representative picture of HOS cell invasion; B is a comparison result of the relative invasion ability of HOS cells; C is a representative picture of 143B cell invasion; D is a comparison result of the relative invasion ability of 143B cells, *** represents the comparison between the overexpression group and the negative control group and the blank control group, P < 0.01;
[0036] Fig.11 Figure 2 is the effect of NEXN on the clone formation of HOS and 143B cells; A is a representative picture of HOS cell clone formation; B is the comparison result of the number of HOS cell clone formation, **** represents the difference between the overexpression group and the negative control group and the blank control group, P < 0.01; C is a representative picture of 143B cell clone formation; D is the comparison result of the number of 143B cell clone formation, ** represents the difference between the overexpression group and the negative control group and the blank control group, P < 0.01.
[0037] Fig.12 Comparison results of nude mice weights in different groups; A is the comparison results of nude mice weights in 3 groups related to HOS cells; ** represents P < 0.001; B is the comparison results of nude mice weights in 3 groups related to 143B cells; ** represents P < 0.001;
[0038] Fig.13 The following are representative images of nude mice after sacrifice and bilateral tibiae after dissection; A is a gross photo of tibiae tumors in nude mice in the HOS group; B is a gross photo of tibiae tumors in nude mice in the 143B group;
[0039] Fig.14 Representative images of in vivo imaging, X-rays, and HE-stained sections of bilateral tibiae and lung tissues of nude mice in the HOS group;
[0040] Fig.15 Representative images of in vivo imaging, X-rays, and HE-stained sections of bilateral tibiae and lung tissues of nude mice in group 143B;
[0041] Fig.16 Representative HE pathological images of the brain, liver, kidney, pancreas, spleen, small intestine, and testis of nude mice with and without lung metastasis;
[0042] Fig.17 Representative images of HE-stained sections and NEXN immunohistochemistry of tumor tissues of nude mice in group 143B;
[0043] Fig.18 Representative images of HE-stained sections and NEXN immunohistochemistry of tumor tissues of nude mice in the HOS group. DETAILED DESCRIPTION
[0044] The present invention is further described in detail below in conjunction with embodiments.
[0045] Those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the art or the product specifications are used. If the manufacturer of the materials or equipment used is not specified, they are all conventional products that can be purchased.
[0046] Unless otherwise specified in the present invention, the percentages are percentages by volume. Unless otherwise specified in the present invention, cell culture was carried out at 37°C and 5% CO 2 Culture in a cell culture incubator.
[0047] definition
[0048] NEXN gene high expression type osteosarcoma cell line: refers to a NEXN gene high expression type osteosarcoma cell line in which the NEXN gene expression level is higher than the NEXN gene expression level in the parental osteosarcoma cell line, for example, the difference is 3-6 times, preferably 4-5 times.
[0049] Unless otherwise specified, percentages in the present invention are percentages by volume.
[0050] Example 1: Transcriptome sequencing and analysis of osteosarcoma patient tissues
[0051] 1. Source of patient tissue samples
[0052] Tissue specimens were collected from patients who were hospitalized in the Third Affiliated Hospital of Kunming Medical University and diagnosed with osteosarcoma (OS) by clinical, imaging, and pathological analysis. The present study was approved by the Medical Ethics Committee of the Third Affiliated Hospital of Kunming Medical University, tissue specimens and clinical parameters of patients were collected, and informed consent was obtained from all patients.
[0053] Six pairs of 12 samples that passed quality control were collected (including tumor and adjacent tissues from three patients with metastatic osteosarcoma and tumor and adjacent tissues from three patients with non-metastatic osteosarcoma). The general information of the patients is shown in Table 1.
[0054] Table 1 General information of osteosarcoma patients included in the sequencing
[0055]
[0056] 2. Transcriptome sequencing
[0057] The experimental process was performed according to the standard protocol provided by Oxford Nanopore Technologies (ONT). RNA was extracted from the 12 tissue samples mentioned above, and the samples were subjected to third-generation transcriptome sequencing using the Nanopore sequencing platform. The statistical data of the sequencing results are shown in Table 2.
[0058] Table 2 Statistics of sequencing results
[0059]
[0060] Note: N stands for paratumor tissue and T stands for tumor tissue.
[0061] 3. Identification of differentially expressed genes (DEGs)
[0062] Compare transcriptome data from different samples to find differentially expressed genes.
[0063] The results show:
[0064] In the normal group and tumor group: that is, 6 cases of peritumoral tissues (normal group) and 6 cases of tumor tissues (tumor group), 2949 differentially expressed genes were identified, of which 1296 genes were upregulated in tumor tissues relative to peritumoral tissues, and 1653 genes were downregulated. Some of the upregulated and downregulated genes are shown in Table 3.
[0065] In the non-metastasis group and the metastasis group, i.e., 3 tumor tissues without metastasis (non-metastasis group) and 3 tumor tissues with metastasis (metastasis group), 790 differentially expressed genes were identified, of which 485 genes were up-regulated and 305 genes were down-regulated in the metastatic tumor tissues relative to those in the non-metastasis tumor tissues. Details of some of the up-regulated and down-regulated genes are shown in Table 4.
[0066] Table 3 List of some genes up-regulated and down-regulated in osteosarcoma tumor tissue and adjacent tissue
[0067]
[0068] Table 4 List of some genes up-regulated and down-regulated in tumor tissues of osteosarcoma without metastasis and osteosarcoma with lung metastasis
[0069]
[0070] (IV) Construction of protein interaction network of T&N target gene set members
[0071] Protein interaction database (string) was used to perform protein interaction (PPI) analysis on the target gene set members. Cytoscope software was used to construct the PPI network of genes interacting with NEXN (the gene alias is Nexilin), and the MCODE plug-in was used to construct the core network of the target gene set PPI network including NEXN. The screening conditions were Degree Cutoff=2, Cluster finding=Haircut, Node Score Cutoff=0.2, K-core=2, Max. Depth=100. Figure 1 .
[0072] Figure 1 is the protein interaction network of the target gene set members; among them, Figure 1 A shows the PPI network of genes interacting with NEXN. Figure 1 B shows the core network including NEXN in the PPI network of the target gene set.
[0073] This shows that the NEXN gene is involved in many protein interactions.
[0074] Example 2: qPCR verification of differentially expressed genes
[0075] For the DEGs screened by transcriptome sequencing and bioinformatics analysis, four genes, RGS5, NEXN, EDN1, and CAV1, were selected for qPCR verification. The GAPDH gene was used as an internal reference, and the primer sequences are shown in Table 5.
[0076] Table 5 Gene primer information
[0077]
[0078] Total RNA was extracted from the above 12 samples, reverse transcribed into cDNA, and then qPCR tests were performed using primers of the above four genes and SYBR Green as the fluorescent molecule. The reaction system and reaction procedure are shown in Tables 6 and 7.
[0079] Among them, the specific manufacturers and models of reagents and products used are as follows:
[0080] The reverse transcription kit was TUREscript 1st Stand cDNA SYNTHESIS Kit, Advantix;
[0081] 2×SYBR® Green master mix, DF, China;
[0082] 200 μL RNase-free PCR reaction tube, AXGEN;
[0083] 1.5mL RNase-free EP tube, GCS;
[0084] Low white PCR reaction tube, bio-rad;
[0085] Optical sealing film, bio-rad.
[0086] Table 6 qPCR reaction system
[0087]
[0088] Table 7 qPCR amplification procedure
[0089]
[0090] For comparison between peritumoral tissue (NC) and tumor tissue (OS), see Figure 2 A to Figure 2 D, Comparison of patients without metastasis (NM-OS) and patients with metastasis (M-OS) see Figure 2 E to Figure 2 H, in each case the average value of similar organizations was used for calculation.
[0091] pass Figure 2 It can be seen that compared with adjacent tissues, RGS5, NEXN, EDN1, and CAV1 genes were significantly downregulated in osteosarcoma tumor tissues. Compared with patients without metastasis, RGS5 and NEXN were upregulated, EDN1 was downregulated, and there was no significant difference in CAV1 gene in tissues of patients with metastasis. The expression levels of the two groups were consistent with the sequencing results.
[0092] It can be seen that the combined detection of the above genes can well distinguish osteosarcoma tissue from healthy tissue, and can distinguish patients without metastasis from patients with metastasis to a certain extent. The primer combination shown in Table 5 has diagnostic value for osteosarcoma.
[0093] Example 3: RNA fluorescence in situ hybridization (FISH)
[0094] The coding sequence of human NEXN gene is shown in SEQ ID NO.11.
[0095] The amino acid sequence of human NEXN protein is shown in SEQ ID NO.12.
[0096] Taking the coding sequence of human NEXN gene as the target sequence, an RNA probe targeting NEXN gene was designed and synthesized. The probe sequence is as follows:
[0097] 5'-CY3-agucuucuccauccaguauuucuccuuc-3' (SEQ ID NO. 13).
[0098] Using RNA fluorescence in situ hybridization, the 12 tissues used in Example 1 were made into paraffin sections, the sections were hybridized with the probe shown in SEQ ID NO. 13, and then stained. The sections were observed and images were collected under an upright fluorescence microscope. DAPI was used to stain the cell nucleus.
[0099] Select a field of view of adjacent tumor tissue, a field of view of lung metastatic osteosarcoma tissue (M-OS), and a field of view of non-metastatic osteosarcoma tissue (NM-OS), and summarize the photos into Figure 3 , where the scale bar is 100 microns. The present invention uses RNA FISH to clarify the localization of NEXN in normal tissues and tumor tissues. The results show that NEXN is distributed in the cytoplasm and cell membrane of normal tissues and tumor tissues, and is mainly located in the cell membrane.
[0100] Example 4: Western blot
[0101] The present invention also collected normal tissues and tumor tissues from 4 patients with osteosarcoma without metastasis and 4 patients with osteosarcoma metastasis. Rabbit anti-NEXN IgG prepared with human NEXN protein as antigen was used as primary antibody (Affinity Antibody Company, USA), goat anti-rabbit IgG labeled with horseradish peroxidase HRP was used as secondary antibody (purchased from Invitrogen Company, USA), ECL working solution was used as reaction substrate, and the gray value of the band was analyzed by Image J software. The expression of NEXN gene in normal tissues and tumor tissues of patients was detected by WB. The WB detection spectrum and spectrum gray statistical graph can be found in Figure 4 .
[0102] exist Figure 4 middle, Figure 4 A shows that in the group of patients without lung metastasis, NEXN protein was lowly expressed in tumor tissues compared with normal tissues; Figure 4 B is the gray value statistical analysis of NEXN protein expression in the group of patients without lung metastasis. Figure 4 C shows that in the group of patients with lung metastasis, NEXN protein was lowly expressed in tumor tissues compared with normal tissues; Figure 4 D is the statistical analysis of grayscale value of NEXN protein expression in patients with lung metastasis, * represents P <0.05, *** represents P <0.0001.
[0103] Example 5: Expression of NEXN in normal osteoblasts and osteosarcoma cell lines
[0104] The human osteoblast hFOB1.19 cells used in the present invention were purchased from Zhejiang Baidi Biotechnology Co., Ltd., and the human osteosarcoma cell line HOS cells and 143B cells were purchased from Guangzhou Saiku Biotechnology Co., Ltd.
[0105] Total RNA was extracted from hFOB1.19 cells, HOS cells, 143B cells, MG63 cells, U2OS cells, and Saos-2 cells, and reverse transcribed into cDNA. The expression of NEXN gene was detected by qPCR using GAPDH gene as internal reference and SYBR Green as fluorescent molecule. The qPCR reaction system and reaction procedure are shown in Tables 6 and 7. The primer sequences are shown in Table 8. The results are shown in Figure 5 .
[0106] The results showed that compared with hFOB1.19, the expression levels of NEXN in HOS and 143B were decreased. Figure 5 *** represents P < 0.01.
[0107] Table 8 Gene primer information
[0108]
[0109] Example 6: Construction of HOS and 143B cell types with high NEXN gene expression
[0110] 1. Construction of recombinant plasmid
[0111] The lentiviral vector plasmid pLV4ltr-PGK-ZsGreen(2A)Puro-CMV was purchased from Nanjing Qingke Biotechnology Co., Ltd.
[0112] The coding sequence of the NEXN gene was inserted into the downstream of the CMV promoter of the lentiviral vector plasmid pLV4ltr-PGK-ZsGreen(2A)Puro-CMV (control plasmid) to obtain the recombinant plasmid - NEXN overexpression lentiviral vector plasmid pLV4ltr-PGK-ZsGreen(2A)Puro-CMV-NEXN. The structure diagram of the recombinant plasmid can be found in Figure 6 .
[0113] The specific method is:
[0114] (1) The NEXN gene was amplified by PCR for full gene synthesis and the PCR product was recovered;
[0115] The PCR amplification reaction system is:
[0116] Mix primer 50pmol / μL / primer 0.5μL;
[0117] 2×T8 High-Fidelity Master Mix 25μL;
[0118] dH 2 HO Add to 50μL.
[0119] 2×T8 High-Fidelity Master Mix is the TSE111 product of Qingke Biotechnology.
[0120] PCR amplification reaction conditions: 95°C for 3 min; 95°C for 25 s, 60°C for 20 s, 72°C for 40 s, 25 cycles in total; 72°C for 1 min; 10°C hold;
[0121] The sequences of all primers in the Mix primers used are shown in Table 9.
[0122] Table 9
[0123]
[0124] (2) Enzyme digestion of the lentiviral vector plasmid pLV4ltr-PGK-ZsGreen(2A)Puro-CMV to obtain a linearized vector;
[0125] Vector enzyme digestion system:
[0126] Carrier (1ug / μL) 2μL;
[0127] 10×buffer 10μL;
[0128] XhoI 1 μL;
[0129] BamHI 1 μL;
[0130] dH 2 HO Add to 100μL.
[0131] The enzyme digestion conditions were: 37°C water bath for 1 h, and recovery by gel electrophoresis.
[0132] XhoI and BamHI were purchased from Thermo Fisher Scientific.
[0133] (3) The PCR product and the linearized vector were recombined to obtain the NEXN overexpression lentiviral vector plasmid pLV4ltr-PGK-ZsGreen(2A)Puro-CMV-NEXN;
[0134] Recombination reaction system:
[0135] PCR product 4 μL;
[0136] Linearized vector 3.5 μL;
[0137] 2.5 μL of homologous recombination enzyme.
[0138] Among them, the homologous recombinase is the TSV-S1 product of Qingke Biotechnology.
[0139] The recombination reaction conditions are: 50°C water bath for 25 minutes, standing at room temperature for 2-3 minutes to lower the temperature, and then transforming the competent state.
[0140] 2. Lentiviral packaging
[0141] (1) Cell culture
[0142] One day before transfection, subculture 293T cells that have grown to 80% into T75 culture flasks at a ratio of 1:2. Prepare for transfection when the cells have grown to 80%.
[0143] (2) Plasmid transfection
[0144] With the total amount of vector unchanged, the operation was carried out according to the instruction manual of Lipo293™ (Biyuntian: C0521) transfection reagent, and the lentiviral vector plasmid pLV4ltr-PGK-ZsGreen(2A)Puro-CMV (control plasmid) and NEXN overexpression lentiviral vector plasmid pLV4ltr-PGK-ZsGreen(2A)Puro-CMV-NEXN were mixed with auxiliary plasmids, and 293T cells were transfected. The transfection medium formula used for transfection was 90% DMEM+10% FBS. The auxiliary plasmids were PSPAX2 and PMD2.G;
[0145] The mass ratio of lentiviral vector plasmid, PSPAX2 and PMD2.G is 5:3:2.
[0146] (3) Replace the culture medium
[0147] 18-24 hours after transfection, carefully aspirate the cell culture medium and replace it with new transfection medium;
[0148] (4) Culture medium collection
[0149] 24h and 48h after the medium change, aspirate the cell culture supernatant into a 50mL centrifuge tube and add fresh transfection medium. At 96h, aspirate the cell culture supernatant into a 50mL centrifuge tube and discard the cells. Filter the supernatant with a 0.45μm sterile filter and transfer to a new centrifuge tube.
[0150] (5) Virus concentration
[0151] According to the instructions of the PEG lentivirus purification kit (Yinmao Shengye: P1201), the cell supernatant was concentrated and purified to obtain the recombinant lentivirus. Finally, the recombinant lentivirus precipitate was dissolved in DMEM complete culture medium, aliquoted at 200 μL / tube, and stored at -80°C.
[0152] Preferably, the 24h and 48h cell culture supernatants after filtration are collected and stored in a 4°C refrigerator; the 96h cell supernatants are filtered and collected and then concentrated together for virus concentration. When concentrating the virus, it is preferably centrifuged at room temperature and 500g for 10 minutes.
[0153] 3. Lentiviral transfection
[0154] (1) Infection and drug killing
[0155] One day before infection, 1×10 5 HOS cells and 143B cells were plated in two 24-well plates, with 3×10 cells per well. 4 cells, add 500 μL DMEM complete culture medium to each well, and take the corresponding amount of virus packaged with the recombinant plasmid and the control plasmid to infect the cells according to the MOI value = 50, and culture overnight.
[0156] Replace the screening culture medium containing puromycin at concentrations of 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 μg / mL, with two replicates for each well. Replace the screening culture medium containing the corresponding concentration of puromycin 24 hours after drug addition; observe cell survival after 48 hours, and replace 500 μL of screening culture medium without puromycin; the puromycin concentration of the experimental group with no cell survival after 72 hours is the screening concentration, which is 1 μg / mL. Among them, the screening culture medium is 89% MEM + 10% FBS + 1% double antibody.
[0157] The experimental groups were as follows: HOS overexpression experimental group (HOS NEXN-OE, HOS cells transfected with lentivirus using recombinant plasmid), HOS negative control group (HOS NEXN-NC, HOS cells transfected with lentivirus using control plasmid), HOS blank control group (HOS blank control, HOS cells not transfected with virus), 143B overexpression experimental group (143B NEXN-OE, 143B cells transfected with lentivirus using recombinant plasmid), 143B negative control group (143B NEXN-NC, 143B cells transfected with lentivirus using control plasmid), and HOS blank control group (143B blank control, 143B cells not transfected with virus).
[0158] 24 hours after the virus infected the cells, the screening culture medium was changed and 1 μg / mL puromycin was added to kill the cells for 2 days.
[0159] (2) Single clone
[0160] After counting the pooled cells, the cell concentration was controlled at 1-1.5 cells per 100 μL by limiting dilution to obtain a cell suspension. The cell suspension was inoculated into a 96-well plate, with 100 μL of cell suspension per well, and the culture medium was 89% MEM + 10% FBS + 1% double antibody.
[0161] (3) Picking single clones
[0162] At 37°C and 5% CO 2 Culture in a cell culture incubator for 7-10 days, observe the single clones growing in the 96-well plate under a microscope, and mark the wells where the single clones are located. Digestion with 0.25% trypsin is terminated, and the culture is expanded by subculture. When the number of cells reaches 1×10 6 After 100 cells were isolated, the precipitate was collected for subsequent testing, and the remaining small amount of cells was expanded and kept as seeds.
[0163] The effect of NEXN on HOS and 143B colony formation is shown in Figure Fig.11 shown.
[0164] Example 7: Activity determination of HOS and 143B cells overexpressing NEXN gene
[0165] 1. NEXN gene expression test
[0166] There were 6 groups: HOS overexpression experimental group, HOS negative control group, HOS blank control group, 143B overexpression experimental group, 143B negative control group, and HOS blank control group. The expression of NEXN gene was determined by qPCR method in 6 groups, and the expression of NEXN protein was determined by WB method. The results are shown in Figure 7 . Figure 7 middle, Figure 7 A shows the expression of NEXN in HOS cells after transfection detected by qPCR; Figure 7 B shows the expression of NEXN in 143B cells after transfection detected by qPCR; Figure 7 C shows the expression of NEXN protein in HOS and 143B cells after transfection detected by Western Blot; Figure 7 D shows the results of quantitative analysis of NEXN protein expression; *** represents P < 0.01;
[0167] The results showed that this indicated that HOS and 143B cells with high expression of the NEXN gene were successfully constructed.
[0168] 2. Cell proliferation
[0169] For the six groups of HOS overexpression experimental group, HOS negative control group, HOS blank control group, 143B overexpression experimental group, 143B negative control group, and HOS blank control group, the CCK-8 method was used to calculate the cell survival rate based on the OD value, and the survival curve was drawn. Figure 8 ,in, Figure 8 A is the CCK-8 experiment of HOS cells; Figure 8 B is the CCK-8 experiment of 143B cells; *** represents the difference between the overexpression group and the negative control group and the blank control group, P < 0.01.
[0170] The results showed that the proliferation ability of cells with high NEXN expression was significantly enhanced, and NEXN may promote the metastasis of osteosarcoma.
[0171] 3. Scratch test
[0172] (1) For the six groups of cells, HOS overexpression experimental group, HOS negative control group, HOS blank control group, 143B overexpression experimental group, 143B negative control group, and HOS blank control group, use a marker pen and a ruler to draw horizontal lines on the back of the 6-well plate with a spacing of 1 cm, and cross the wells horizontally. Set up 3 replicate wells for each group.
[0173] (2) Digest the cells with 0.25% trypsin for 3 min and then inoculate them into 6-well plates at a volume of 10 6 The cells were cultured in DMEM medium containing 10% fetal bovine serum at 37°C and 5% CO 2 Culture in a cell culture incubator. When the cell density reaches 70-80%, wash the cells with PBS, use a 200 μL sterile pipette tip perpendicular to the cell plane, scratch with a ruler, wash the scratched cells with PBS, replace with DMEM culture medium, and then take pictures at 0 h. Continue to place in 37°C, 5% CO 2 Culture cells in a cell culture incubator.
[0174] (3) Perform microscopic observation and take photos at the same location 12 h and 24 h after scratching.
[0175] (4) Image J software was used to calculate the scratch area at different time points and compare the migration rates of cells in different groups. The calculation formula was: (initial scratch area - scratch area at a specific time point) / initial scratch area.
[0176] The results of NEXN promoting the lateral migration of HOS and 143B cells are shown in Fig. 9 ,in, Fig. 9 A is a picture of HOS cell scratches; Fig. 9 B is the comparison result of relative scratch healing rate of HOS cells; Fig. 9 C is a picture of 143B cell scratches; Fig. 9D is the comparison result of relative scratch healing rate of 143B cells, *** represents the comparison between overexpression group and negative control group and blank control group, P < 0.01.
[0177] The cell scratch test showed that the overexpression experimental group (HOS and 143B cells overexpressing NEXN) had enhanced cell scratch healing ability compared with the negative control group and the blank control group. The above experimental results show that NEXN significantly affects the migration ability of osteosarcoma cells.
[0178] 4. Transwell migration and invasion assay
[0179] Transwell migration assay:
[0180] (1) Add 600 μL of DMEM medium containing 10% fetal bovine serum into a 24-well plate until it just touches the bottom of the Transwell chamber.
[0181] (2) The cells in the logarithmic growth phase of the HOS overexpression experimental group, HOS negative control group, HOS blank control group, 143B overexpression experimental group, 143B negative control group, and HOS blank control group were digested and centrifuged, and the cells were counted after resuspending. 200 μL of 5×10 4 Each group of cells was cultured in 3 replicate wells at 37°C and 5% CO 2 Incubate the cells in a cell culture incubator for 24 h.
[0182] (3) Aspirate the culture medium in the Transwell chamber and the 24-well plate, gently rinse the upper chamber of the chamber three times with PBS, and aspirate all the liquid;
[0183] (4) Add 800 μL / well of 4% paraformaldehyde to the lower chamber of the chamber and place it at room temperature for 30 min. Discard the 4% paraformaldehyde and add ddHO. 2 O Clean the chamber.
[0184] (5) Add 800 μL / well of crystal violet dye to the lower chamber of the cell to stain the cells and shake slowly on a shaker for 20 min.
[0185] (6) Remove the crystal violet stain, wet a cotton swab, and gently wipe the cells in the chamber with the cotton swab. Then wash with PBS until the background is clear and let dry.
[0186] (7) Seal the slides with neutral gum and observe the cells under a microscope. Analyze the number of cells that have penetrated the membrane (i.e., the number of migrated cells) and perform statistical analysis.
[0187] Transwell invasion assay:
[0188] (1) Dilute the prepared Matrige gel to 300 μg / mL with serum-free DMEM medium, 200 μL per well, and add it to the Transwell chamber precooled to 4°C. Gently shake the chamber so that all pores on the membrane of the chamber are covered with Matrige gel to avoid the formation of bubbles. Place it in a 37°C incubator for 30 min to allow the gel to solidify.
[0189] (2) After the matrix gel has solidified, add 600 μL / well of DMEM medium into the lower chamber of the 24-well Transwell plate.
[0190] (3) Digest and centrifuge the cells in the logarithmic growth phase (1000 rpm, 3 min), resuspend them in serum-free DMEM medium, and count the cells. Add 200 μL of 5×10 4 Each group of cells was cultured in serum-free DMEM medium, with 3 replicates per well, at 37°C and 5% CO 2 Cell culture incubator: Culture cells for 24 h.
[0191] (4) Aspirate the culture medium in the Transwell chamber and the 24-well plate, gently rinse the upper chamber of the chamber three times with PBS, and aspirate all the liquid.
[0192] (5) Add 800 μL / well of 4% paraformaldehyde to the lower chamber and place at room temperature for 30 min.
[0193] (6) Aspirate the fixative, wash the lower chamber of the cell three times with PBS, add 800 μL / well of crystal violet stain to stain the cells, and shake slowly on a shaker for 20 min.
[0194] (7) Remove the crystal violet stain, wet a cotton swab, and gently wipe the cells in the chamber with the cotton swab. Then wash with PBS until the background is clear and let dry.
[0195] (8) Seal the slides with neutral gum and observe the cells under a microscope. Analyze the number of cells that penetrate the membrane, which is the number of invasive cells. Count the results and analyze them.
[0196] Fig.10 The figure shows the effect of NEXN on the invasion ability of HOS and 143B cells. Fig.10 A is a representative picture of HOS cell invasion; Fig.10 B is the comparison result of relative invasion ability of HOS cells; Fig.10 C is a representative picture of 143B cell invasion; Fig.10 D is the comparison result of relative invasion ability of 143B cells; *** represents the difference between the overexpression group and the negative control group and the blank control group, P < 0.01.
[0197] Transwell invasion assay showed that the overexpression experimental group had enhanced cell invasion ability compared with the negative control group and the blank control group. The above experimental results show that NEXN significantly affects the invasion ability of osteosarcoma cells.
[0198] Example 8: Construction of a nude mouse model of osteosarcoma orthotopic tibia tumor formation and lung metastasis
[0199] 1. Animal husbandry
[0200] Thirty 4-week-old BALB / C male nude mice were purchased from Sbefor (Beijing) Biotechnology Co., Ltd. (License No.: SCXK (Beijing) 2019-0010). After receiving the nude mice, their weight was recorded. The nude mice were first placed under SPF conditions, with a temperature of 20-25°C and a humidity of 50-70% in the barrier, with a 12-hour day and night alternation. They were given standard rodent feed and drinking water for 1-2 weeks to maintain good growth. The experimental animal welfare ethics were carried out in accordance with relevant laws and regulations. The animal experiments in this study were reviewed and approved by the Experimental Ethics Review Committee of the Third Affiliated Hospital of Kunming Medical University.
[0201] 2. In situ inoculation of tumor cells to establish a lung metastasis model
[0202] For the six groups of cells in Example 6, there were 5 nude mice in each group, for a total of 30. In each group, a complete medium prepared with a basal medium DMEM + 10% fetal bovine serum FBS + 1% penicillin-streptomycin antibiotics was used to expand the six groups of cells. The culture conditions were 37°C and 5% CO2 incubator. After the cells were expanded and cultured, they were digested with 0.25% trypsin, centrifuged and the supernatant was discarded, and then resuspended and diluted with 1×PBS to a concentration of 5×10 6 / mL to obtain a cell suspension.
[0203] Nude mice were anesthetized by intraperitoneal injection of 0.7 (w / w)% sodium pentobarbital solution (solvent: normal saline) at a dose of 60 mg / kg. After successful anesthesia, a disposable sterile syringe with a needle (1 mL) was used to inject the cell suspension of the corresponding group into the bone marrow cavity of both tibiae of nude mice. The injection volume was 50 μL to construct an orthotopic osteosarcoma tumor model. The 6 groups of orthotopic osteosarcoma tumor models were respectively recorded as HOS-OE group, HOS-NC group, HOS-PBS group, 143B-OE group, 143B-NC group, and 143B-PBS group;
[0204] After successful inoculation, continue to keep the mice under SPF conditions and pay attention to the tumor formation and growth of the nude mice.
[0205] Example 9: Physiological and pathological changes in osteosarcoma model animals
[0206] 1. Measurement of nude mouse body weight
[0207] For the mice in the HOS-OE group, HOS-NC group, HOS-PBS group, 143B-OE group, 143B-NC group, and 143B-PBS group, the body weight was measured and recorded on the day of inoculation, and then measured and recorded once a week, and finally the body weight change curve of nude mice after inoculation was drawn. Fig.12 .
[0208] Fig.12 A is the comparison of the body weight of nude mice in three different groups related to HOS cells; ** represents P < 0.001; Fig.12 B is the comparison of the weight of nude mice in different groups of 143B cells; ** represents P < 0.001. It can be seen that compared with the HOS-PBS group, the inoculation of different tumor cells in the HOS-OE group and the HOS-NC group significantly reduced the weight of mice; compared with the 143B-PBS group, the inoculation of different tumor cells in the 143B-OE group and the 143B-NC group significantly reduced the weight of mice.
[0209] Representative images of nude mice sacrificed and dissected bilateral tibiae are shown in Fig.13 .
[0210] 2. In vivo imaging of small animals
[0211] After the nude mice formed tumors, the luminescent substrate D-luciferin potassium salt (purchased from Shanghai Biyuntian Company) was injected into the left lower abdominal cavity at a dose of 3.0 mg / 20 g. After 8 minutes, the experimental nude mice were anesthetized with 0.7% sodium pentobarbital. After successful anesthesia, they were transferred to the small animal in vivo imaging system Perkin Elmer for imaging. Analyze the fluorescence and record the corresponding data information. Fig.14 First column, Fig.15 The first column shows that the mice inoculated with tumors glowed, while the mice in the blank control group did not glow, which indicates that tumors were formed in the mice and tumor mice were successfully constructed.
[0212] (III) Small Animal X-ray Examination
[0213] After the nude mice were tumor-forming, they were anesthetized with 0.7% sodium pentobarbital. After successful anesthesia, they were transferred to the digital X-ray machine sample imaging system and the animals were placed in a prone position at the center of the imaging board for imaging. After the imaging, the in situ tumor formation was determined based on the destruction of the tibia and other bones throughout the body and the formation of soft tissue tumors, and then statistical analysis and comparison were performed. The results can be found in Fig.14 The second column, Fig.15 Second column.
[0214] 4. Nude mouse dissection
[0215] 28 days after inoculation, the experimental animals were euthanized, the dead nude mice were properly arranged, and the ruler was placed, and then the data was recorded. Mosquito forceps, micro forceps, micro scissors and other related surgical instruments were used to dissect the nude mice, and the tibial tumors and lung tissues were removed respectively, classified and photographed for preservation. The removed tissues were fixed with 4% paraformaldehyde for histopathological examination. The HE staining results of the sections can be found in Fig.14 The third to sixth columns, Fig.15 Columns 3 to 6.
[0216] Tumor formation in nude mice in each group: In vivo imaging and pathological HE sections of small animals showed that neither in situ tumor formation nor lung metastasis formation was observed in the HOS-PBS group nor in the 143B-PBS group; in situ tumor formation was observed in the HOS-NC group nor in the 143B-NC group, but no lung metastasis was observed; in situ tumor formation and lung metastasis were observed in the HOS-OE group nor in the 143B-OE group. Small animal X-ray showed that there was no bone destruction in the bilateral tibiae of nude mice in the HOS-PBS group and the 143B-PBS group, while obvious bone destruction and soft tissue tumor formation were observed in the bilateral tibiae of nude mice in the HOS-NC group, the 143B-NC group, the HOS-OE group, and the 143B-OE group. The bone destruction in the HOS-OE group and the 143B-OE group was more serious than that in the corresponding HOS-NC group and the 143B-NC group, and the soft tissue tumors in the HOS-OE group and the 143B-OE group were also larger than those in the corresponding HOS-NC group and the 143B-NC group. The results of the two OS cell lines were consistent (see Fig.13 , 14 , 15).
[0217] 5. Histopathological examination of nude mice
[0218] The lung, brain, liver, kidney, pancreas, spleen, small intestine, and testis tissues of nude mice in the HOS-OE group were taken for routine pathological HE staining. The results showed that tumor cells were found in the lung tissue, but not in the brain, liver, kidney, pancreas, spleen, small intestine, and testis tissues (see Fig.16 ). This result is the same as that of the 143B-OE group.
[0219] It can be seen that the osteosarcoma cells with high expression of NEXN inoculated through the tibia can metastasize to the lung tissue, but will not metastasize to the brain, liver, kidney, pancreas, spleen, small intestine, and testicular tissue. Example 8 of the present invention successfully constructed a model mouse with osteosarcoma tibia in situ tumor formation and lung metastasis.
[0220] 6. Immunohistochemistry of tumor NEXN
[0221] To further verify the expression of NEXN after in situ tumor formation, the in situ tumors and adjacent tumor tissues of nude mice in the HOS-OE, HOS-NC, HOS-PBS, 143B-OE, 143B-NC, and 143B-PBS groups were dissected and immunohistochemically verified. The primary antibody added to the sections was HPR-labeled anti-NEXN monoclonal antibody (purchased from Affinity Antibody Company, USA). TM 3 HRP reagent (purchased from Fuzhou Maixin Biotechnology Co., Ltd.) and freshly prepared ΜLtra DAB color development reagent (purchased from Fuzhou Maixin Biotechnology Co., Ltd.) were used for color development, and image acquisition was performed using Image Viewer software. Fig.17 and Fig.18 , among which, the photo of 143B cells can be found in Fig.17 , HOS cells are shown in Fig.18 .
[0222] The results showed that the expression of NEXN in normal tissues adjacent to the tumor was higher than that in the corresponding tumor tissues of the HOS-OE group, HOS-NC group, 143B-OE group, and 143B-NC group, which was consistent with the trend of human tissue immunohistochemistry detection. The expression of NEXN in tumor tissues of the HOS-OE group and 143B-OE group was higher than that in the corresponding HOS-NC group and 143B-NC group, which also proved that the present invention successfully constructed a cell line overexpressing NEXN.
[0223] In summary, the present invention successfully constructed a nude mouse model of osteosarcoma tibia orthotopic tumor formation and lung metastasis, which can be used for the pathological and pharmacological research of metastatic osteosarcoma and improve the research and development efficiency of metastatic osteosarcoma.
[0224] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. A method for constructing a NEXN gene highly expressed osteosarcoma cell line. It is characterized in that The steps include: Step (1), plasmid construction: The coding sequence of the NEXN gene was inserted into the downstream of the CMV promoter of the lentiviral vector plasmid pLV4ltr-PGK-ZsGreen(2A)Puro-CMV to obtain the NEXN overexpression lentiviral vector plasmid pLV4ltr-PGK-ZsGreen(2A)Puro-CMV-NEXN; The amino acid sequence of the NEXN gene is shown in SEQ ID NO.12; Step (2), lentiviral packaging: the NEXN overexpression lentiviral vector plasmid pLV4ltr-PGK-ZsGreen(2A)Puro-CMV-NEXN obtained in step (1) is co-transfected into 293T cells together with PSPAX2 and PMD2.G plasmids using a liposome method to obtain a recombinant lentivirus; Step (3), cell line construction: using the recombinant lentivirus prepared in step (2) to infect human osteosarcoma cell line cells, replacing the culture medium with a screening medium 24 hours after infection, and adding puromycin to the screening culture medium for screening to obtain positive cells; the human osteosarcoma cell line cells are human osteosarcoma cell line HOS cells or human osteosarcoma cell line 143B cells; wherein the screening culture medium replaced 24 hours after infection is 89% MEM + 10% FBS + 1% dual antibody; Step (4), expansion culture: the screened positive cells are expanded and cultured to construct an osteosarcoma cell line with high expression of the NEXN gene.
2. The method for constructing a NEXN gene highly expressed osteosarcoma cell line according to claim 1, It is characterized in that In step (2), during transfection, the transfection culture medium used was 90% DMEM + 10% FBS.
3. The method for constructing a NEXN gene highly expressed osteosarcoma cell line according to claim 1, It is characterized in that In step (3), puromycin is added to the screening culture medium to a concentration of 1 μg / mL.
4. The NEXN gene highly expressed osteosarcoma cell line obtained by the method for constructing a NEXN gene highly expressed osteosarcoma cell line according to any one of claims 1 to 3.
5. Use of the method for constructing a NEXN gene high-expressing osteosarcoma cell line according to any one of claims 1 to 3 and the obtained NEXN gene high-expressing osteosarcoma cell line in drug screening.
6. A method for constructing an animal model of osteosarcoma with lung metastasis. It is characterized in that The NEXN gene high expression osteosarcoma cell line constructed by the method for constructing a NEXN gene high expression osteosarcoma cell line according to any one of claims 1 to 3 comprises the following steps: The osteosarcoma cell line with high expression of NEXN gene was inoculated into the tibia bone marrow cavity of animals to obtain the osteosarcoma model animal with lung metastasis.
7. The method for constructing an animal model of osteosarcoma with lung metastasis according to claim 6, Features: The animal is a mouse.
8. The method for constructing an animal model of osteosarcoma with lung metastasis according to claim 6, Features: The NEXN gene high-expression osteosarcoma cell line was injected into the bilateral tibial medullary cavity of the animal, with an injection dose of 200-300 cells per side.
9. Use of the osteosarcoma model animal with lung metastasis constructed by the method for constructing the osteosarcoma model animal with lung metastasis according to claim 6 in screening therapeutic drugs for osteosarcoma with lung metastasis.
